Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
28.41 USD
-1.22%
Market Closed
Updated:
May 4, 2024
Royalty Pharma PLC
Cash from Investing Activities
|
Royalty Pharma PLC
Cash from Investing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Royalty Pharma PLC
NASDAQ:RPRX
|
Cash from Investing Activities
-$2.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
$878m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$21.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$32.3B
|
CAGR 3-Years
-96%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$14.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$7.2B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
See Also
What is Royalty Pharma PLC's Cash from Investing Activities?
Cash from Investing Activities
-2.1B
USD
-2.1B
USD
Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's Cash from Investing Activities amounts to -2.1B USD.
What is Royalty Pharma PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
9%
9%
Over the last year, the Cash from Investing Activities growth was -101%. The average annual Cash from Investing Activities growth rates for Royalty Pharma PLC have been 9% over the past three years .
You don't have any saved screeners yet
